Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) increases morbidity and mortality. Our study aimed to investigate the role of baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) as a predictor of AKI following TAVI. All consecutive TAVI patients were included in the analysis, except patients with dialysis and those with a GFR < 15 ml/min/1.73 m2 at baseline. Rates of AKI after TAVI were assessed according to the updated valve academic research consortium definitions using AKIN classification in three stages. NT-proBNP was measured at baseline. One-year mortality rates were assessed. We included 1973 patients treated with TAVI between January 2006 and December 2016. Median IQR age was 81.0 77.0;84.0 years, the STS score was 6.2 3.9;9.0, and the logEuroScore was 14.5 9.0;23.0. 30-day and one-year mortality was 5.1 % and 16.1 % for all patients, respectively. Multivariate analysis revealed that patients with NT-proBNP levels higher than two times above the upper level of normal (ULN) had an increased risk for AKI after TAVI compared to patients with NT-proBNP levels < 2× ULN (OR 1.40 1.03–1.91). Routine assessment of baseline NT-proBNP levels might be an additional tool to identify patients at increased risk for AKI after TAVI. •Acute kidney injury is associated with adverse outcomes in TAVI patients.•Baseline NT-proBNP is an independent predictor of AKI after TAVI.•Early identification of patients at high risk for AKI is crucial.•High-risk patients may benefit from further reducing the periprocedural amount of CM.